The Swiss and Danish consortium participants will merge their expertise to develop a platform for the automated production of 3D cell-based assays.
The simplest cell-based assays are in vitro, 2D monolayer cultures, which lack physiological relevance and functionality, notably when it comes to cancer models. This drives the development of more complex multilayer 3D cell-based assays, such as organoids or Organ-on-Chips.
Readily3D’s unique volumetric printing system, the Tomolite bioprinter, enables the contactless generation of entire 3D living objects within seconds. CelVivo’s clinostat incubator, the ClinoStar, provides an autonomous semiautomatic 3D cell and tissue culture system with a low shear force and high diffusion rate.
The joint project will combine these two stress-free and cell-friendly technologies for automated production of complex 3D-shaped bioconstructs into an incubation environment, while leveraging the photonics expertise of the University of Southern Denmark (SDU) and Ecole Polytechnique Fédérale de Lausanne (EPFL) for the design of an advanced light engine. Bioneer, a Danish RTO (Research and Technology Organization), will demonstrate the scalability and applicability of the new product for drug screening applications.
This project VOLTA-E!3908 has received funding from the Eurostars-3 joint programme with co-funding from the European Union’s Horizon Europe research and innovation programme. The Swiss partners also acknowledges co-funding by Innosuisse, the Swiss Innovation Agency. In addition, the Danish partners acknowledges co-funding by Innovation Fund Denmark (IFD).
